N-isoquinolin-6-yl-2-(3-methoxybenzylamino)acetamide | 920513-63-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-isoquinolin-6-yl-2-(3-methoxybenzylamino)acetamide
• 英文别名: N-(Isoquinolin-6-yl)-2-((3-methoxybenzyl)amino)acetamide；N-isoquinolin-6-yl-2-[(3-methoxyphenyl)methylamino]acetamide
• CAS: 920513-63-9
• 化学式: C₁₉H₁₉N₃O₂
• 分子量: 321.379
• InChiKey: MHGUYABKNWFTMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  63.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• 6-Aminoisoquinoline Compounds
  申请人：deLong Mitchell A.

  公开号：US20080167340A1

  公开（公告）日：2008-07-10

  6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  提供了影响、抑制或减少激酶作用的6-氨基异喹啉化合物。还提供了包括治疗有效量的6-氨基异喹啉化合物和药用可接受载体的药物组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或疾病条件，如癌症、肥胖和青光眼的各种方法。
• [EN] NOVEL ISOQUINOLINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'ISOQUINOLINE
  申请人：BANYU PHARMA CO LTD

  公开号：WO2010117084A1

  公开（公告）日：2010-10-14

  The present invention relates to a compound represented by a formula (I): wherein: R is independently from each other a lower alkyl group and the like, X is an oxygen atom or a sulfur atom, Y is a lower alkylene group having 1 to 6 carbon atoms, R1 is a phenyl group and the like which may be substituted by a halogen atom and the like, and any CH2 in the following: (I-1) may be substituted by a lower alkyl group, and R2 is a phenyl group or a pyridinyl group which may be substituted by a lower alkyl group and the like, m is 0, 1, 2 or 3, and n is 0 or 1, or a pharmaceutically acceptable salt thereof.

  本发明涉及一种由式(I)表示的化合物：其中：R分别是低碳烷基基团等，X是氧原子或硫原子，Y是具有1至6个碳原子的低碳烷基基团，R1是苯基等，可以被卤原子等取代，以下的任何CH2均可被低碳烷基基团取代，R2是苯基或吡啶基，可以被低碳烷基等取代，m为0、1、2或3，n为0或1，或其药学上可接受的盐。
• Isoquinoline compounds
  申请人：deLong A. Mitchell

  公开号：US20070142429A1

  公开（公告）日：2007-06-21

  Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  提供了含有G的异喹啉化合物，能够影响、抑制或减少G蛋白受体激酶的作用。同时还提供了含有治疗有效量的异喹啉化合物和药用载体的制药组合物。还提供了使用这些化合物和/或组合物来影响疾病状态或条件，如癌症、骨质疏松和青光眼等的各种方法。
• ISOQUINOLINE COMPOUNDS
  申请人：deLong Mitchell A.

  公开号：US20090069371A1

  公开（公告）日：2009-03-12

  Isoquinoline compounds with G are provided that influence, inhibit or reduce the action of a G-protein receptor kinase. Pharmaceutical compositions including therapeutically effective amounts of the isoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, osteoporosis and glaucoma are also provided.

  本发明提供了含有G的异喹啉化合物，其能够影响、抑制或减少G蛋白受体激酶的作用。同时还提供了包含治疗有效量的异喹啉化合物和药用载体的制药组合物。本发明还提供了使用这些化合物和/或组合物来影响癌症、骨质疏松症和青光眼等疾病状态或病情的各种方法。
• 6-AMINOISOQUINOLINE COMPOUNDS
  申请人：deLong Mitchell A.

  公开号：US20110183965A1

  公开（公告）日：2011-07-28

  6-Amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

  本发明提供了影响、抑制或减少激酶作用的6-氨基异喹啉化合物。还提供了包括治疗有效量的6-氨基异喹啉化合物和药学上可接受的载体的制药组合物。还提供了使用这些化合物和/或组合物影响疾病状态或病症，如癌症、肥胖和青光眼的各种方法。